Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Heading into the final third of the year, Cathie Wood isn't trading in her racing stripes. The founder, CEO, and chief investment officer at Ark Invest continues to outfit her collection of exchange-traded funds with aggressive growth opportunities. With most of Ark's ETFs delivering modest single-digit positive returns so far in 2026, she's not going to shy away from making moves to fine-tune her portfolios.

What is she buying these days? Nvidia (NASDAQ: NVDA), Broadcom (NASDAQ: AVGO), and Intellia Therapeutics (NASDAQ: NTLA) were among the half-dozen stocks on Ark Invest's shopping list on Friday. They are all existing positions. Let's take a closer look at what she may find so appealing in all three investments.

Ark Invest's Cathie Wood. Image source: Getty Images.

1. Nvidia

Nvidia stock did everything it could have last week to earn its market cap crown. The only company with a market cap above $5 trillion easily exceeded expectations in Wednesday afternoon's earnings release. Revenue more than doubled for the fiscal second quarter, soaring 106% to hit a record $96.2 billion. Some figured the analysts were aiming too high with their target of 97% top-line growth.

A 117% jump in data center revenue -- accounting for 93% of the quarter's results -- led the way. It's the fourth consecutive report of sharply accelerating growth.

• Q2 FY 2026: 56%
• Q3 FY 2026: 63%
• Q4 FY 2026: 73%
• Q1 FY 2027: 85%
• Q2 FY 2027: 106%

Once again, the bottom line found a way to stay ahead of the monster revenue jump. Adjusted earnings per share soared 120% to $2.22, also comfortably ahead of market expectations. As strong as the results were, its guidance was even better.

Nvidia now expects 70% in revenue growth in fiscal 2028, which starts in February. This is the real jaw-dropping announcement, as analysts were bracing for just a 45% jump on the top line next year. Wall Street pros are now scrambling to jack up their forecasts for next year. They now see Nvidia earning $15.31 a share next year, up from the $13.01 they were modeling just a week ago.

The shares rose nearly 9% on Thursday following the news, but gave back more than half of those gains on Friday. The silver lining behind the downticks is that they make the shares that much cheaper. You can now buy Nvidia for 14 times next year's adjusted earnings.

2. Broadcom

Broadcom stock is another name working on its fourth straight quarter of accelerating top-line growth. The semiconductor and tech infrastructure solutions provider has seen its quarterly revenue gains rise from 20% a year ago to 48% for the fiscal second quarter, which it will report on Wednesday afternoon this week.

The streak should easily extend to five quarters of accelerating growth this week. Its revenue guidance three months ago had investors bracing for an 84% surge. Analysts are now holding out for an 85% increase with a 92% jump on the bottom line.

Is this another rerun of Nvidia last week, where a "beat and raise" performance after the market close on Wednesday finds growth forecasts outpacing the reaction on Wall Street? Broadcom trades at a reasonable 19 times next year's earnings. If it's somehow cheaper at the other end of this critical financial update, don't be surprised if Wood keeps buying.

3. Intellia Therapeutics

The one Ark fund that is doing much better than the single-digit returns of most of the rest is the ARK Genomic Revolution ETF (NYSEMKT: ARKG). It's up 64% so far in 2026, nearly doubling over the past year. A strong market for biotechs and gene-editing stocks has fueled monster gains for the fund.

Intellia Therapeutics is in the gene-editing space, developing next-gen treatments based on CRISPR. Despite the bullish long-term prospects for Intellia and its peers, the stock has shed more than half of its value from last October's highs (and that wasn't even the all-time high set years earlier).

It's still winning over analysts. Jonathan Miller at Evercore ISI became the last to upgrade the stock earlier this month, encouraged despite a recent pause in a critical phase 3 trial for a potential liver toxicity signal. Miller's new price target of $24 is nearly twice the stock's current price. Intellia isn't expected to turn a profit anytime soon, but flush with cash and with no debt outside of its lease obligations, it has time to see its potential blockbusters through the approval process.

Rick Munarriz has positions in Nvidia. The Motley Fool has positions in and recommends Broadcom, Intellia Therapeutics, and Nvidia. The Motley Fool has a disclosure policy.